Reports Q1 revenue $0.9M, consensus $2.42M. “During the first quarter, we made significant strides in advancing both our internal and partnered programs according to plan,” said Sean McClain, Founder and CEO. “I am especially excited by our progress, which demonstrates the potential of our generative AI platform to disrupt the economics of drug discovery and to design differentiated therapeutics addressing significant unmet medical needs for patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
- Absci Corp. (ABSI) Q1 Earnings Cheat Sheet
- Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
- Absci expects cash to fund operations into 1H27
- Absci reports Q4 EPS (25c), consensus (25c)
